Listen to our CEO, Young Kwon discuss Alchemab’s innovative platform and its novel approach to drug discovery on the pharmaphorum podcast. Learn More.

Cambridge, UK, September 5, 2023 – Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that Young Kwon, PhD, Chief Executive Officer, will participate in a fireside chat at the Wells Fargo 2023 Healthcare Conference on 7 September 2023 at 4:30 p.m. ET. Please click here to […]

Our CEO Young Kwon was delighted to speak with Richard Staines of the Optimum  Perspectives Podcast on how Alchemab is revolutionizing antibody drug discovery with a novel alternative to the classic “choose a target” approach. Listen Here.

Alchemab CEO Young Kwon and Taylor Mixides from Drug Target Review discuss how Alchemab’s research has significant potential to transform the landscape of neurodegenerative disease research and improve the lives of those affected by these challenging conditions. Please click here to read more.

Alchemab was delighted to be featured in Drug Target Review in a profile by Izzy Wood. In the article, Izzy and Olivia Cavlan, our Chief Corporate Development and Strategy Officer, discuss the untapped potential of AI in drug target discovery and how Alchemab’s platform aims to identify common antibodies in resilient individuals and uncover the […]

Cambridge, UK, June 22, 2023 – Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate, at the Antibody Industrial Symposium in Tours, France, 22-23 June 2023. ATLX-1088 is a potential first-in-class human antibody targeting CD33, a […]

Alchemab’s Donna Finch, Head of Translational and Clinical Science, presented data on a potential first-in-class disease modifying therapeutic for Huntington’s Disease at the annual CHDI Huntington’s Disease Therapeutics Conference in Dubrovnik, Croatia, on the 26 April 2023. Our innovative, target agnostic discovery platform, which combines data analysis of hundreds of millions of individual antibodies with […]